Denosumab Biosimilar (XGEVA® reference)

About mAbxience

mAbxience is a global, vertically integrated biotech firm with a dual focus on developing its own portfolio of biosimilar monoclonal antibodies and offering comprehensive CDMO services. With over a decade of experience, it operates state-of-the-art GMP manufacturing facilities in Europe and South America, boasting a combined cell culture capacity of 50,000L. The company leverages its in-house R&D expertise to improve patient access to high-quality biologics worldwide, recently achieving significant regulatory milestones like FDA approval for denosumab biosimilars.

Therapeutic Areas